EDAP Edap Tms S.a.
USHealthcareAs of 2026-06-02 09:30
Why EDAP matters now
Edap Tms S.a. (EDAP) is a US stock in Healthcare. The latest InvestLog snapshot shows $4.76 with -0.52% on the session and $178.2M in market capitalization; recent performance reads 1-month +10.07% and YTD +44.53%.
The latest financial table shown here is Q1 2026, with revenue of $17.9M, net income of $-9.1M, and EPS of $-0.24. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -8.0%.
The latest indexable market news headline is "Edap Tms Unveils FocalTherics Pivot, Targets 40% Growth on HIFU Expansion" from MarketBeat.
Additional event context on this page matters because analyst consensus is Hold with a median target of $10.00; recent insider activity includes Mobeck Kenneth S. filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
17.85
P/S
2.43
EV/EBITDA
-7.85
DCF Value
$-47.45
FCF Yield
-8.0%
Div Yield
0.0%
Margins & Returns
Gross Margin
43.4%
Operating Margin
-34.7%
Net Margin
-41.5%
ROE
-137.4%
ROA
-42.7%
ROIC
-60.6%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $17.9M | $-9.1M | $-0.24 |
| Q4 2025 | $21.9M | $-9.4M | $-0.25 |
| FY 2025 | $70.7M | $-29.3M | $-0.78 |
| Q3 2025 | $16.2M | $-5.9M | $-0.13 |
Analyst Ratings
Consensus
Hold
Target (Consensus)
$10.00
Target (Median)
$10.00
Target Range
$10.00 - $10.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Medical - Devices
Country
FR
Exchange
—
Beta
-0.10
EDAP TMS S.A., a medical technology firm headquartered in Lyon, France, since its inception in 1979, innovates, manufactures, and globally distributes advanced, minimally invasive medical devices. With a primary focus on addressing urological diseases through sophisticated solutions, the company operates across Asia, France, the United States, and other international markets. Its business operations are divided into three distinct segments: 1. High Intensity Focused Ultrasound (HIFU): This segment concentrates on developing and advancing HIFU technology for the minimally invasive treatment of urological and various other clinical indications. Its product portfolio encompasses the Ablatherm, an ultrasound-guided robotic HIFU device for organ-confined prostate cancer; the Ablatherm Fusion, which features proprietary fusion software that merges MRI and ultrasound images for precise targeting; and the Focal One, a robotic HIFU device specifically designed for the focal therapy of prostate cancer. The segment also provides necessary disposables, leasing and treatment-related services, and ongoing maintenance. 2. Extracorporeal ShockWave Lithotripsy (ESWL): This division is responsible for manufacturing and marketing lithotripters utilizing ESWL technology to treat urinary tract stones. Its flagship, the Sonolith i-move, is an extracorporeal shockwave lithotripter well-suited for small to mid-sized hospitals, with accompanying sales of disposable parts and electrodes. 3. Distribution Services (DIST): This segment oversees the marketing, distribution, and servicing of various medical products from third-party manufacturers, such as lasers and micro-ultrasound systems. This segment's offerings also extend to device leasing, the sale of disposables and spare parts, and comprehensive maintenance support. The company serves a broad customer base, including hospitals, urology clinics, and research institutions, leveraging both its direct marketing, sales, and service platform, as well as a network of third-party distributors and agents.